Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)

Inclusion * Histologically confirmed de novo AML as evidenced by absence of an antecedent hematologic disease of \> 1 months duration, prior chemotherapy, prior radiation therapy or myelodysplastic cytogenetics (as per exclusion criteria) * Life expectancy, with treatment, \> 3 months * Age \> 18 years * ECOG performance status 0, 1 or 2 * Adequate organ function to receive protocol specified chemotherapy Exclusion * Subjects in blast transformation of chronic myeloid leukaemia (CML) * Patients with secondary AML (Received previous chemotherapy or radiotherapy) * Previous treatment for AML * Patients with AML FAB type M3 (Acute Promyelocytic Leukemia, APL) or M7 * High risk (Unfavourable) cytogenetics \[(-5/del(5q), -7/del(7q), t(8;21) with del (9q) or complex karyotype, inv(3q), abn 11q23, 20q, 21q, del(9q), t(6;9), t(9;22), abn 17p, complex karyotypes(\>3 abnormalities)\]